New trial for blindness rewrites the genetic code – Medical Xpress

Posted: March 20, 2017 at 11:40 am

March 20, 2017 New trial for blindness rewrites the genetic code. Credit: Shutterstock

Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.

Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible loss of vision.

The trial is being run by Nightstarx Ltd (Nightstar), a biopharmaceutical spinout company of Oxford developing gene therapies for inherited retinal diseases, and researchers from the University of Oxford. On 16 March 2017, a 29 year old British man became the first patient with X-linked retinitis pigmentosa to undergo gene therapy. The operation took place at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Foundation Trust.

Gene therapy uses a virus to insert the correct copy of a defective gene into cells, and has shown promise for treating genetic causes of blindness. Unfortunately, the gene involved with retinitis pigmentosa, RPGR, is highly unstable, making gene therapy particularly challenging. The RPGR gene's unusual genetic code has made it very difficult to work with in the laboratory.

However, a research team led by Professor Robert MacLaren from the University of Oxford has reprogrammed the genetic code of RPGR to make it more stable, but in a way that does not affect its function. This has allowed the gene to be delivered reliably by a viral vector into retinal cells.

The current trial is the first in the world to test a treatment for retinitis pigmentosa caused by RPGR.

Robert MacLaren, Professor of Ophthalmology at the University of Oxford, who is leading the trial said: "The effect of RPGR-related disease on families with retinitis pigmentosa is devastating and we have spent many years working out how to develop this gene therapy. Changing the genetic code is always undertaken with great caution, but the new sequence we are using has proven to be highly effective in our laboratory studies.

"The genetic code for all life on Earth is made up of four letters G, T, A and C. In RPGR, however, half of the gene comprises only two letters A and G. This makes the gene very unstable and prone to mutations, making it a lead cause of blindness in patients with retinitis pigmentosa. RPGR is vital for the light sensitive cells at the back of the eye."

The trial has started at the Oxford University Hospitals NHS Foundation Trust and is sponsored by Nightstar, a University of Oxford spin-out company. It is supported by the NIHR Biomedical Research Centre at the Oxford University Hospitals NHS Foundation Trust. Up to 30 patients will be enrolled.

David Fellows, Chief Executive Officer of Nightstar remarked: "We are delighted to report the advancement of this exciting gene therapy program into patients. If successful, this gene therapy has the potential to transform the lives of many patients (and their families) around the world."

Dr Aniz Girach, Chief Medical Officer of Nightstar commented: "The current trial is an open-label dose-escalation study designed to enrol at least 24 patients who will receive a single subretinal injection of the RPGR gene therapy. The primary goal of the study is to assess safety and tolerability of this gene therapy over a 12 month period."

Explore further: Mutations in CWC27 result in a spectrum of developmental conditions

An international team of researchers has discovered that mutations in the human gene CWC27 result in a spectrum of clinical conditions that include retinal degeneration and problems with craniofacial and skeletal development. ...

Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases ...

Preceyes B.V., a spin-off of Eindhoven University of Technology, and Nightstar (UK) have entered into a collaboration for the development of a high-precision drug delivery technology in the eye. Nightstar will use the Preceyes ...

Using a new technology for repairing disease genesthe much-talked-about CRISPR/Cas9 gene editingUniversity of Iowa researchers working together with Columbia University Medical Center ophthalmologists have corrected ...

Researchers at UCL Institute of Ophthalmology and Moorfields Eye Hospital with funding from Fight for Sight, in collaboration with a team from Baylor College of Medicine in the USA, have discovered a new retinitis pigmentosa ...

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness ...

Like almost all light-sensitive living beings, human beings follow biological rhythms set on a period of about 24 hours. The circadian clock (from Latin "circa" and "dies", which means "about a day") therefore describes the ...

The majority of genes associated with nephrotic syndrome (NS) in humans also play pivotal roles in Drosophila renal function, a conservation of function across species that validates transgenic flies as ideal pre-clinical ...

Britain's Newcastle University says its scientists have received a license to create babies using DNA from three people to prevent women from passing on potentially fatal genetic diseases to their childrenthe first time ...

Columbia University Medical Center (CUMC) researchers have discovered a common genetic variant that greatly impacts normal brain aging, starting at around age 65, and may modify the risk for neurodegenerative diseases. The ...

Studies of autoimmune and inflammatory diseases have identified hundreds of genetic regions thought to be associated with these conditions. At the same time, studies of expression quantitative trait loci (eQTLs) have revealed ...

Genetic variation in the non-coding DNA could give rise to language impairments in children and other neurodevelopmental disorders including schizophrenia, autism, and bipolar disorder, scientists from the Max Planck Institute ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original here:
New trial for blindness rewrites the genetic code - Medical Xpress

Related Posts

Comments are closed.

Archives